Genetic Technologies Limited logo

Genetic Technologies LimitedNASDAQ: GENE

Profile

Sector:

Healthcare

Country:

Australia

IPO:

06 September 2005

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$3.73 M
-91%vs. 3y high
11%vs. sector
-vs. 3y high
-vs. sector
-60%vs. 3y high
69%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Thu, 14 Nov 2024 14:30:00 GMT
$0.77$0.00(0.00%)

Dividend

No data over the past 3 years
No data over the past 3 years
No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

GENE Latest News

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
prnewswire.com12 November 2024 Sentiment: POSITIVE

Avidity expands  its leading RNA delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: AOC 1086 to treat PLN Cardiomyopathy and AOC 1072 to treat PRKAG2 Syndrome AOC 1072 and AOC 1086 preclinical data demonstrated robust siRNA delivery to the heart and targeted knockdown with potent reduction of approximately 80% in cardiac PLN mRNA and PRKAG2 mRNA Avidity introduces next-generation technology innovations demonstrating improved siRNA delivery in skeletal muscle and increased durability in preclinical studies AOC 1072 preclinical data will be presented at American Heart Association (AHA) Scientific Sessions 2024 Volume 11 of virtual investor and analyst series today, Tuesday, Nov. 12 at 8:00 a.m. ET SAN DIEGO , Nov. 12, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it has expanded beyond rare skeletal muscle disorders and is opening up a new therapeutic field, precision cardiology, to address the root cause of genetic diseases of the heart.

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference
globenewswire.com30 October 2024 Sentiment: POSITIVE

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's

Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance
benzinga.com29 October 2024 Sentiment: POSITIVE

GeneDx Holdings WGS stock is trading higher on Tuesday.

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
globenewswire.com15 October 2024 Sentiment: POSITIVE

Myriad's MyRisk®  test is the first hereditary cancer test integrated into Flatiron's OncoEMR® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Flatiron Health, a leading health tech company dedicated to expanding the possibilities of point of care solutions in oncology. This collaboration allows physicians to order Myriad's MyRisk®  Hereditary Cancer Test and view the results of the test directly in Flatiron's cloud-based Electronic Medical Record (EMR) platform, OncoEMR®.

Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
globenewswire.com15 October 2024 Sentiment: POSITIVE

Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November

XORTX Initiates Precision Medicine Program
globenewswire.com09 October 2024 Sentiment: POSITIVE

Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism

CENTOGENE Data on Novel Genetic Risk Factor for Parkinson's Disease in The Lancet Neurology
globenewswire.com25 September 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced data from the Company's Rostock International Parkinson's Disease (ROPAD), further supporting the association of a RAB32 gene mutation with Parkinson's disease (PD). The study, published in The Lancet Neurology , builds on research from Emil K. Gustavsson and colleagues, who previously identified the RAB32 c.213C>G (p.Ser71Arg; dbSNP rs200251693) variant as a novel monogenic cause of PD.

23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating
globenewswire.com25 September 2024 Sentiment: POSITIVE

Provides 23andMe+ Premium members with insight into their likelihood of experiencing emotional eating based on their genetics Provides 23andMe+ Premium members with insight into their likelihood of experiencing emotional eating based on their genetics

Dyne Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference
globenewswire.com23 September 2024 Sentiment: POSITIVE

WALTHAM, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan's 8th Annual Genetic Medicines Conference being held in New York on Monday, September 30, 2024 at 2:00 p.m. ET.

Join Genetic Technology's Exclusive Live Investor Webinar and Q&A Session on October 2
globenewswire.com23 September 2024 Sentiment: POSITIVE

MELBOURNE, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on October 2, 2024, at 4:15 p.m. ET.

  • 1(current)

What type of business is Genetic Technologies Limited?

Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, it offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. It has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery; and research collaboration with Harvard University, Ohio State University, and Washington University. The company was incorporated in 1987 and is headquartered in Fitzroy, Australia.

What sector is Genetic Technologies Limited in?

Genetic Technologies Limited is in the Healthcare sector

What industry is Genetic Technologies Limited in?

Genetic Technologies Limited is in the Diagnostics & Research industry

What country is Genetic Technologies Limited from?

Genetic Technologies Limited is headquartered in Australia

When did Genetic Technologies Limited go public?

Genetic Technologies Limited initial public offering (IPO) was on 06 September 2005

What is Genetic Technologies Limited website?

https://genetype.com

Is Genetic Technologies Limited in the S&P 500?

No, Genetic Technologies Limited is not included in the S&P 500 index

Is Genetic Technologies Limited in the NASDAQ 100?

No, Genetic Technologies Limited is not included in the NASDAQ 100 index

Is Genetic Technologies Limited in the Dow Jones?

No, Genetic Technologies Limited is not included in the Dow Jones index

When was Genetic Technologies Limited the previous earnings report?

No data

When does Genetic Technologies Limited earnings report?

Next earnings report date is not announced yet